Protein Polymer Technologies to merge with Thuris

New York, Nov. 22 - Protein Polymer Technologies, Inc. said it has agreed to merge with Thuris Corp.

"Bringing our organizations together accelerates both companies' strategic plans and creates a biotechnology device leader with the products, pipeline, infrastructure and financial resources to grow faster and create sustainable shareholder value beyond what either company could achieve separately," said William N. Plamondon III, chief executive officer of Protein Polymer Technologies, in a news release.

Thuris is a privately held biopharmaceutical company focused on medical device solutions to aid in drug development and diagnosis of central nervous system disorders including Mild Cognitive Impairment and Alzheimer's Disease.

Thuris is also developing pharmaceuticals for select central nervous system orphan and niche indications ranging from ischemia-related conditions, brain inflammation and Huntington's disease.

It has 510(k) clearance from the Food and Drug Administration for a non-invasive medical device, the NeuroGraph, which assists in the diagnosis of neurological and psychiatric disorders over a broad range of brain-related conditions.

Protein Polymer Technologies is a San Diego-based biotechnology device company working on protein design and synthesis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.